BioCryst Pharmaceuticals Inc
BCRX7.130USD
0.000
Cierre 12/17, 16:00（ET）Cotizaciones retrasadas 15 min
1.50BCap. mercado
PérdidaP/E TTM
Más Datos de BioCryst Pharmaceuticals Inc Compañía
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Información de BioCryst Pharmaceuticals Inc
Símbolo de cotizaciónBCRX
Nombre de la empresaBioCryst Pharmaceuticals Inc
Fecha de salida a bolsaMar 04, 1994
Director ejecutivoGayer (Charles K)
Número de empleados580
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 04
Dirección4505 Emperor Blvd Ste 200
CiudadDURHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27703-8457
Teléfono19198591302
Sitio Webhttps://www.biocryst.com/
Símbolo de cotizaciónBCRX
Fecha de salida a bolsaMar 04, 1994
Director ejecutivoGayer (Charles K)
Ejecutivos de BioCryst Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
144.35K
-32.87%
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
91.22K
+0.87%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
70.87K
+21.41%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
64.27K
+24.14%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
41.79K
+1.91%
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
144.35K
-32.87%
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
91.22K
+0.87%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2023
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States (Country)
140.34M
85.91%
Outside of U.S.
16.50M
10.10%
Other
6.52M
3.99%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.03%
RA Capital Management, LP
7.27%
Deerfield Management Company, L.P.
5.78%
State Street Investment Management (US)
4.66%
Otro
63.93%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.03%
RA Capital Management, LP
7.27%
Deerfield Management Company, L.P.
5.78%
State Street Investment Management (US)
4.66%
Otro
63.93%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
37.13%
Investment Advisor/Hedge Fund
27.37%
Hedge Fund
21.91%
Venture Capital
7.27%
Research Firm
6.22%
Individual Investor
1.12%
Pension Fund
0.77%
Private Equity
0.43%
Bank and Trust
0.38%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
564
213.88M
103.62%
+15.67M
2025Q3
578
198.21M
105.86%
-3.39M
2025Q2
567
200.28M
97.51%
+20.52M
2025Q1
541
179.39M
95.89%
-21.22M
2024Q4
539
169.89M
99.17%
-5.66M
2024Q3
532
176.74M
101.53%
-3.05M
2024Q2
510
179.40M
103.13%
-5.65M
2024Q1
522
185.07M
103.37%
-28.22M
2023Q4
527
182.31M
101.91%
+1.15M
2023Q3
518
181.69M
109.53%
+2.20M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
20.50M
9.77%
-1.12M
-5.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
17.04M
8.12%
-849.42K
-4.75%
Jun 30, 2025
Deerfield Management Company, L.P.
12.17M
5.8%
+7.48M
+159.36%
Sep 12, 2025
State Street Investment Management (US)
8.51M
4.05%
+691.99K
+8.86%
Jun 30, 2025
Kynam Capital Management LP
8.46M
4.03%
-464.78K
-5.21%
Jun 30, 2025
Two Sigma Investments, LP
8.52M
4.06%
+3.25M
+61.72%
Jun 30, 2025
UBS Financial Services, Inc.
5.61M
2.67%
+3.21M
+133.63%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
4.28M
2.04%
+4.08M
+2103.71%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.05M
2.41%
+93.97K
+1.89%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Genomics Immunology and Healthcare ETF
2.49%
Invesco Biotechnology & Genome ETF
2.26%
Virtus LifeSci Biotech Products ETF
1.13%
State Street SPDR S&P Biotech ETF
0.66%
ALPS Medical Breakthroughs ETF
0.64%
Invesco NASDAQ Future Gen 200 ETF
0.47%
Direxion Daily S&P Biotech Bull 3X Shares
0.41%
First Trust Small Cap Growth AlphaDEX Fund
0.26%
Principal U.S. Small-Cap ETF
0.23%
Inspire Small/Mid Cap ESG ETF
0.2%
Ver más
iShares Genomics Immunology and Healthcare ETF
Proporción2.49%
Invesco Biotechnology & Genome ETF
Proporción2.26%
Virtus LifeSci Biotech Products ETF
Proporción1.13%
State Street SPDR S&P Biotech ETF
Proporción0.66%
ALPS Medical Breakthroughs ETF
Proporción0.64%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.47%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.41%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.26%
Principal U.S. Small-Cap ETF
Proporción0.23%
Inspire Small/Mid Cap ESG ETF
Proporción0.2%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de BioCryst Pharmaceuticals Inc?
Los cinco principales accionistas de BioCryst Pharmaceuticals Inc son:
The Vanguard Group, Inc. posee 20.50M acciones, lo que representa el 9.77% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 17.04M acciones, lo que representa el 8.12% del total de acciones.
Deerfield Management Company, L.P. posee 12.17M acciones, lo que representa el 5.80% del total de acciones.
State Street Investment Management (US) posee 8.51M acciones, lo que representa el 4.05% del total de acciones.
Kynam Capital Management LP posee 8.46M acciones, lo que representa el 4.03% del total de acciones.
The Vanguard Group, Inc. posee 20.50M acciones, lo que representa el 9.77% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 17.04M acciones, lo que representa el 8.12% del total de acciones.
Deerfield Management Company, L.P. posee 12.17M acciones, lo que representa el 5.80% del total de acciones.
State Street Investment Management (US) posee 8.51M acciones, lo que representa el 4.05% del total de acciones.
Kynam Capital Management LP posee 8.46M acciones, lo que representa el 4.03% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de BioCryst Pharmaceuticals Inc?
Los tres principales tipos de accionista de BioCryst Pharmaceuticals Inc son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
RA Capital Management, LP
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
RA Capital Management, LP
¿Cuántas instituciones poseen acciones de BioCryst Pharmaceuticals Inc (BCRX)?
A fecha de 2025Q4, 564 instituciones poseen acciones de BioCryst Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 213.88M, lo que representa el 103.62% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -2.24%.
¿Cuál es la mayor fuente de ganancias de BioCryst Pharmaceuticals Inc?
El FY2025Q2, el segmento empresarial -- generó la ganancia más alta para BioCryst Pharmaceuticals Inc, ascendiendo a -- y representando el --% de la ganancia total.
